Search: id:"swepub:oai:gup.ub.gu.se/300763" >
Effects of Evolocum...
-
Taskinen, Marja-Riitta
(author)
Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
- Article/chapterEnglish2021
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/300763
-
https://gup.ub.gu.se/publication/300763URI
-
https://doi.org/10.1161/ATVBAHA.120.315446DOI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Increased risk of atherosclerotic cardiovascular disease in subjects with type 2 diabetes is linked to elevated levels of triglyceride-rich lipoproteins and their remnants. The metabolic effects of PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors on this dyslipidemia were investigated using stable-isotope-labeled tracers. Approach and Results: Triglyceride transport and the metabolism of apos (apolipoproteins) B48, B100, C-III, and E after a fat-rich meal were investigated before and on evolocumab treatment in 13 subjects with type 2 diabetes. Kinetic parameters were determined for the following: apoB48 in chylomicrons; triglyceride in VLDL1 (very low-density lipoprotein) and VLDL2; and apoB100 in VLDL1, VLDL2, IDL (intermediate-density lipoprotein), and LDL (low-density lipoprotein). Evolocumab did not alter the kinetics of apoB48 in chylomicrons or apoB100 or triglyceride in VLDL1. In contrast, the fractional catabolic rates of VLDL2-apoB100 and VLDL2-triglyceride were both increased by about 45%, which led to a 28% fall in the VLDL2 plasma level. LDL-apoB100 was markedly reduced by evolocumab, which was linked to metabolic heterogeneity in this fraction. Evolocumab increased clearance of the more rapidly metabolized LDL by 61% and decreased production of the more slowly cleared LDL by 75%. ApoC-III kinetics were not altered by evolocumab, but the apoE fractional catabolic rates increased by 45% and the apoE plasma level fell by 33%. The apoE fractional catabolic rates was associated with the decrease in VLDL2- and IDL-apoB100 concentrations.Evolocumab had only minor effects on lipoproteins that are involved in triglyceride transport (chylomicrons and VLDL1) but, in contrast, had a profound impact on lipoproteins that carry cholesterol (VLDL2, IDL, LDL). Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02948777.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Björnson, Elias,1988Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xbelia
(author)
-
Kahri, Juhani
(author)
-
Söderlund, Sanni
(author)
-
Matikainen, Niina
(author)
-
Porthan, Kimmo
(author)
-
Ainola, Mari
(author)
-
Hakkarainen, Antti
(author)
-
Lundbom, Nina
(author)
-
Fermanelli, ValentinaGothenburg University,Göteborgs universitet,Institutionen för matematiska vetenskaper,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Department of Mathematical Sciences,Institute of Medicine, School of Public Health and Community Medicine(Swepub:gu)xferva
(author)
-
Fuchs, JohannesGothenburg University,Göteborgs universitet,Core Facilities, Proteomics,Core Facilities, Proteomics(Swepub:gu)xfujoh
(author)
-
Thorsell, Annika,1973Gothenburg University,Göteborgs universitet,Core Facilities, Proteomics,Core Facilities, Proteomics(Swepub:gu)xdannm
(author)
-
Kronenberg, Florian
(author)
-
Andersson, Linda,1973Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, School of Public Health and Community Medicine,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xanlin
(author)
-
Adiels, Martin,1976Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, School of Public Health and Community Medicine,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xadima
(author)
-
Packard, Chris J
(author)
-
Borén, Jan,1963Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Wallenberglaboratoriet,Institute of Medicine, Department of Molecular and Clinical Medicine,Wallenberg Laboratory(Swepub:gu)xborej
(author)
-
Göteborgs universitetInstitutionen för medicin, avdelningen för molekylär och klinisk medicin
(creator_code:org_t)
Related titles
-
In:Arteriosclerosis, thrombosis, and vascular biology1524-4636
Internet link
Find in a library
To the university's database
- By the author/editor
-
Taskinen, Marja- ...
-
Björnson, Elias, ...
-
Kahri, Juhani
-
Söderlund, Sanni
-
Matikainen, Niin ...
-
Porthan, Kimmo
-
show more...
-
Ainola, Mari
-
Hakkarainen, Ant ...
-
Lundbom, Nina
-
Fermanelli, Vale ...
-
Fuchs, Johannes
-
Thorsell, Annika ...
-
Kronenberg, Flor ...
-
Andersson, Linda ...
-
Adiels, Martin, ...
-
Packard, Chris J
-
Borén, Jan, 1963
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Endocrinology an ...
- Articles in the publication
-
Arteriosclerosis ...
- By the university
-
University of Gothenburg